Autolus Therapeutics’ chimeric antigen receptor (CAR) T-cell therapy obecabtagene autoleucel (Aucatzyl) received FDA approval for adults with B-cell precursor acute lymphoblastic leukemia (ALL). The ...

According to research presented at the Society for the Immunotherapy of Cancer Annual Meeting in Houston, TX, the IL15 agonist NKTR-255 (Nektar Therapeutics) reverses lymphopenia caused by ...

1Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 2Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. ...

Deaths from cancer worldwide are estimated to reach 18.5 million in 2050, an 89.7% increase from the approximately 9.7 million deaths seen in 2022, researchers report (JAMA Netw Open 2024 Nov 5 [Epub] ...

A new targeted therapy aimed specifically at FGFR3, TYRA-300, is showing preliminary promise in patients with advanced FGFR3-altered bladder cancer. Partial responses have been seen in an ongoing ...

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...

In preliminary results from the phase II iMMagine-1 trial released today, the BCMA-directed chimeric antigen receptor (CAR) T-cell therapy anitocabtagene autoleucel (anito-cel) did not elicit any ...

2The University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, Texas. 3Department of Genomic Medicine, The University of Texas MD Anderson ...

1Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.

Mol Cancer Ther (2024) 23 (11): 1515.

Under its 2025 Physician Fee Schedule (PFS), the Centers for Medicare & Medicaid Services (CMS) announced that physicians will be paid, on average, nearly 3% less next year compared with 2024 ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.